54 / 88
54
Scientific Programme /
Wednesday, 21 June 2017
WFSBP 2017
WED
P-11
POSTER TOUR
13:00–14:30
Congress Hall A 1
Schizophrenia 2
Chair:
NN
002
A meta-analysis of lipid profile disturbances in
antipsychotic-naive patients with first-episode non-
affective psychosis
Blazej Misiak, Poland
B. Stanczykiewicz, Ł. Łaczmanski, D. Frydecka
003
Elevated levels of Asymmetric Dimethylarginine
(ADMA) in first-episode schizophrenia patients:
A cross-sectional study with meta-analysis
Blazej Misiak, Poland
M. Fleszar, J. Wisniewski, D. Frydecka
004
Impact of val-allele of Catechol-O-Methyl transfer-
ase on frontal executive functions in schizophrenia using
novel MBIAL computerised battery: A case-control study
Narayan R. Mutalik, India
J. P. John, H. HN, S. Jain
005
Altered age-related subcortical trajectories in
familial high-risk of schizophrenia with transition to
psychosis
Synthia Guimond, USA
S. Sarvode, C. Makowski, M. Chakravarty, M. Keshavan
006
Collapsin-response mediator Protein-5 gene
RS13017554 polymorphism and schizophrenia
Sofi Atshemyan, Armenia
R. Zakharyan, A. Arakelyan
007
The role of complexin family single nucleotide
polymorphisms in schizophrenia
Sofi Atshemyan, Armenia
R. Zakharyan, A. Arakelyan
009
Symptomatic differences between remitted schizo-
phrenia and non-remitted schizophrenia
Yeon-Ho Joo, Republic of Korea
S.-Y. Park, J.-S. Lee
011
Medication adherence in schizophrenia: The role
of insight, therapeutic alliance and perceived trauma
David Misdrahi, France
A. Tessier, L. Boyer, F. Baylé, M. Husky, P.-M. Llorca
012
Exploring adherence profile to antipsychotics in
patients with schizophrenia in a 6 month MEMS device
follow-up post discharged study
David Misdrahi, France
A. Tessier, M. Husky, A. C. Lange, B. Vrijens, P.-M. Llorca,
F. Baylé
014
Hallucinations and delusions differ in response to
antipsychotic medication
Jill Bjarke, Norway
I. Sinkeviciute, R. Gjestad, R. A. Kroken, E.-M. Løberg,
H. A. Jørgensen, E. Johnsen
015
Cannabidiol attenuates the behavioral changes
induced by repeated administration of a NMDA recep-
tor antagonist through a 5HT1A receptor-dependent
mechanism
Francisco Guimaraes, Brazil
N. Rodrigues, N. R. Silva, F. V. Gomes
016
Factors predicting personal and social perfor-
mance in schizophrenia patients
Seung-Hyun Kim, Republic of Korea
017
Evidence on the use of antipsychotics for people
at ultra-high risk of psychosis
Adriana Carapucinha, Portugal
R. Trindade, R. Catarino
018
Neurocognition and social cognition in parents
with schizophrenia or Bipolar Disorder
Aja Neergaard Greve, Denmark
J. R. Moellegaard Jepsen, E. L. Rasmussen, D. L. Gantriis,
D. Ellersgaard, C. J. Christiani, K. S. Spang, N. Hemager,
A. Thorup, M. Nordentoft, K. Plessen, O. Mors, V. Bliksted
019
Neurocognitive deficits in patients with early-
onset schizophrenia, and their nonpsychotic siblings
Nora S. Vyas, United Kingdom
L. Burke, M. Sirota, S. Netherwood, P. Caviston, M. Simic,
K. J. Aitchison
020
“No gain, more pain”: Impact of reward on pain
threshold and tolerance to experimental pain (Cold
pressor task) in healthy subjects and patients with
schizophrenia
Noomane Bouaziz, France
V. Moulier, S. Regat, D. Januel, R. Benadhira
021
Niacin response abnormality in patients with
first-episode psychosis: A potential schizophrenia
endophenotype
Fotini Boufidou, Greece
M. Zoga, P. Oulis, V. G. Masdrakis, P. Pliatsika, S. Foteli,
C. Nikolaou